Last reviewed · How we verify
NPH twice-daily
NPH insulin is an intermediate-acting insulin that lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism.
NPH insulin is a long-acting basal insulin that lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | NPH twice-daily |
|---|---|
| Also known as | (Generic) |
| Sponsor | Charles Drew University of Medicine and Science |
| Drug class | Intermediate-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
NPH (Neutral Protamine Hagedorn) insulin is a suspension of insulin crystals complexed with protamine, which slows insulin absorption from subcutaneous tissue compared to regular insulin. This intermediate duration of action (peak effect 4-8 hours, duration 10-16 hours) makes it suitable for twice-daily dosing regimens in diabetes management. It mimics endogenous insulin secretion by promoting glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (PHASE1, PHASE2)
- Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma (PHASE2)
- Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients (PHASE3)
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC (PHASE2)
- Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC (PHASE3)
- Adaptive Immunotherapy for Nasopharyngeal Carcinoma (PHASE3)
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPH twice-daily CI brief — competitive landscape report
- NPH twice-daily updates RSS · CI watch RSS
- Charles Drew University of Medicine and Science portfolio CI